Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
828 Pacific Highway
Suite 2, Level 3
GordonNSW2072
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.00 | 2.50 | 0.03% |
| CAC 40 | 8,274.64 | 33.40 | 0.41% |
| DAX 40 | 24,041.62 | 339.84 | -1.39% |
| Dow JONES (US) | 47,457.22 | 797.60 | -1.65% |
| FTSE 100 | 9,838.00 | 73.42 | -0.74% |
| HKSE | 26,680.12 | 392.91 | -1.45% |
| NASDAQ | 22,870.36 | 536.10 | -2.29% |
| Nikkei 225 | 50,375.84 | 905.99 | -1.77% |
| NZX 50 Index | 13,464.46 | 207.27 | -1.52% |
| S&P 500 | 6,737.49 | 113.43 | -1.66% |
| S&P/ASX 200 | 8,634.50 | 8.90 | 0.10% |
| SSE Composite Index | 4,016.77 | 12.74 | -0.32% |